Omnicell Inc (OMCL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Omnicell Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 35.40 $ — 27% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -2.9% failed
- More than 10% revenue growth is expected for the coming year 5.5% failed
- Share count grows by less than 3% a year 0.3% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 13.9% failed
- Gross margin at 40% or higher and without meaningful erosion 42.9% passed
- Goodwill from acquisitions does not grow faster than revenue 37.4% failed
- Net debt below twice EBITDA 0.1 x EBITDA passed
- Operating cash flow covers the profits of the last three years 502 m passed
- Return on capital at 15% or higher, or up versus two years ago 0.8% passed
- Insiders hold at least 10% or are net buyers 2.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 67.5% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.30 | 2.16 – 2.49 | 1,238 | 42.2% | 7 |
| 12/31/2027 | 2.16 | 1.97 – 2.43 | 1,293 | -6.2% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.34 | – | 307 | 18.60 | 5.20 | 56 | 47 |
| 2025: Q1 | -0.15 | – | 270 | 9.60 | -2.60 | 26 | 15 |
| 2025: Q2 | 0.12 | 47.90 | 291 | 5.00 | 1.90 | 43 | 31 |
| 2025: Q3 | 0.12 | -36.00 | 311 | 10.00 | 1.80 | 28 | 19 |
| 2025: Q4 | -0.05 | -113.20 | 314 | 2.30 | -0.60 | 30 | 20 |
| 2026: Q1 | 0.25 | – | 310 | 14.90 | 3.70 | 55 | 42 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 693 | 6 | 1 | 0.02 | 48 | 432 | 935 |
| 2017 | 716 | 6 | 21 | 0.53 | 25 | 517 | 980 |
| 2018 | 787 | 44 | 38 | 0.93 | 104 | 680 | 1,081 |
| 2019 | 897 | 78 | 61 | 1.43 | 145 | 845 | 1,241 |
| 2020 | 892 | 36 | 32 | 0.74 | 186 | 968 | 1,825 |
| 2021 | 1,132 | 90 | 78 | 1.62 | 232 | 1,147 | 2,143 |
| 2022 | 1,296 | -2 | 6 | 0.12 | 78 | 1,130 | 2,211 |
| 2023 | 1,147 | -35 | -20 | -0.45 | 181 | 1,189 | 2,227 |
| 2024 | 1,112 | 0 | 13 | 0.27 | 188 | 1,243 | 2,121 |
| 2025 | 1,185 | 12 | 2 | 0.04 | 127 | 1,232 | 1,975 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Omnicell, Inc. bietet gemeinsam mit ihren Tochtergesellschaften Gesundheitstechnologie in den USA und international an.
| Employees | 3,580 |
|---|---|
| Headquarters | Fort Worth, TX |
| Address | 4220 North Freeway, 76137 Fort Worth, United States |
| Phone | 877 415 9990 |
| Website | omnicell.com |
| IPO Date | 7. Aug 2001 |
| ISIN | US68213N1090 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Randall A. Lipps | Founder, Executive Chairman & CEO | 1957 |
| Nnamdi N. Njoku | President & COO | 1977 |
| H. Baird Radford III | Executive VP & CFO | 1970 |
| Corey J. Manley J.D. | Executive VP, Chief Legal & Administrative Officer and Corporate Secretary | 1978 |
| Brian H. Nutt | VP, Chief Accounting Officer & Corporate Controller | 1970 |
| Perry A. Genova Ph.D. | Senior VP & CTO | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Lipps Randall A | CHAIRMAN, CEO | Sell | 10,000 | 47.00 | 470,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.